[{"id":"274b6789-cafa-442a-b349-5cb43132ed40","acronym":"","url":"https://clinicaltrials.gov/study/NCT02656849","created_at":"2021-01-18T12:56:12.287Z","updated_at":"2025-02-25T17:23:00.771Z","phase":"Phase 2","brief_title":"BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors","source_id_and_acronym":"NCT02656849","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" MYC • CCNE1 • MCL1","pipe":" | ","alterations":" MYC amplification • CCNE1 amplification • MCL1 amplification","tags":["MYC • CCNE1 • MCL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC amplification • CCNE1 amplification • MCL1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e roniciclib (BAY1000394)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 05/01/2023","study_completion_date":" 05/01/2023","last_update_posted":"2016-07-01"}]